59776-89-5 Usage
General Description
2-(2-OXOPYRROLIDIN-1-YL)ACETOHYDRAZIDE is a chemical compound with the molecular formula C7H11N3O2. It is a hydrazide derivative with a pyrrolidin-2-one core structure. 2-(2-OXOPYRROLIDIN-1-YL)ACETOHYDRAZIDE is derived from both acetohydrazide and 2-oxopyrrolidine, and it has potential applications in pharmaceutical and chemical research due to its interesting biological and chemical properties. It may be used as a building block for the synthesis of biologically active compounds and can also be utilized in the development of new drugs. Furthermore, it has been studied for its potential as an anticancer agent, making it a promising compound for further research and development in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 59776-89-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,7,7 and 6 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 59776-89:
(7*5)+(6*9)+(5*7)+(4*7)+(3*6)+(2*8)+(1*9)=195
195 % 10 = 5
So 59776-89-5 is a valid CAS Registry Number.
InChI:InChI=1/C6H11N3O2/c7-8-5(10)4-9-3-1-2-6(9)11/h1-4,7H2,(H,8,10)
59776-89-5Relevant articles and documents
COMPOUNDS USEFUL IN HIV THERAPY
-
Page/Page column 41; 42, (2019/05/22)
The invention relates to compounds of Formulas (I), (II) and (III) salts thereof, pharmaceutical compositions thereof, as well as methods of treating, curing or preventing HIV in subjects.
Methods for treating an inflammatory condition or inhibiting JNK
-
, (2008/06/13)
This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
On the analysis and stability of dupracetam
Smilowski
, p. 272 - 273 (2007/10/02)
-
